[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 301
1. Wang C, Xu YQ: Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative? Gastroenterology Res; 2008 Dec;1(1):2-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative?
  • : Diphenyl dimethyl bicarboxylate (DDB) has been used in some countries as hepatoprotectant adjuvant in the treatment of liver diseases, such as chronic viral hepatitis, chemical or drug induced hepatic damage.
  • Its early confirmed efficacy is to normalize elevated blood alanine aminotransferase (ALT) from different etiologies, however, it can rarely affect the rest hepatic enzymes.
  • In addition, the lowering or normalization of ALT in most cases occurs during DDB treatment, withdrawal of DDB administration results in ALT re-elevated.
  • Hence, for a long time, it has been only used as adjuvant of liver disease therapy.
  • It is still controversial that whether DDB can be beneficial to liver histology.
  • The normalization of ALT in hepatitis does not indicate therapeutic efficacy if without substantial liver histology improvement.
  • In recent years, more studies showed that DDB might have new therapeutical potentials in liver diseases, it may have the effect of anti-viral, anti-malignancy.
  • These new findings were mostly based on the in vitro or animal experiments, more basic studies and clinical trials are needed to ascertain these efficacies, prior to that stage, it is recommended to be cautious to apply DDB clinically for anti-virus and anti-malignancy purposes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994699.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; adjuvant / dimethyl diphenyl bicarboxylate / liver disease / schisandra chinensis / schisandrin B / viral hepatitis
  •  go-up   go-down


2. Moritani N, Yamada T, Mizobuchi K, Wakimoto M, Ikeya Y, Matsumura T, Mishima K, Iida S: Atypical lipomatous tumor of the tongue: report of a case. Acta Med Okayama; 2010 Aug;64(4):257-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor of the tongue: report of a case.
  • The term atypical lipomatous tumor (ALT) is synonymous with well-differentiated liposarcoma (WDL).
  • This tumor occurs very rarely in the tongue.
  • Although recurrence of ALT/WDL is thought to be unlikely after complete excision, long-term follow-up is necessary when considering the pathologic conditions of this tumor at other sites.
  • A 68-year-old man was referred to our hospital because of a tumor on the left side of his tongue.
  • Upon palpation, the tumor was 12mm in diameter, circumscribed, elastic and hard, well demarcated, movable, and painless.
  • We diagnosed the lesion as a lipoma and extirpated the tumor under local anesthesia.
  • Because the specimen was histopathologically diagnosed as an ALT, as a precaution, we excised an additional 5mm from the area surrounding the original tumor under general anesthesia.
  • [MeSH-major] Liposarcoma / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lipoma / diagnosis. Lipoma / pathology. Male. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802543.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Zhang CF, Zhang CQ, Zhu YH, Wang J, Xu HW, Ren WH: Ginkgo Biloba Extract EGb 761 Alleviates Hepatic Fibrosis and Sinusoidal Microcirculation Disturbance in Patients with Chronic Hepatitis B. Gastroenterology Res; 2008 Dec;1(1):20-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ginkgo Biloba Extract EGb 761 Alleviates Hepatic Fibrosis and Sinusoidal Microcirculation Disturbance in Patients with Chronic Hepatitis B.
  • BACKGROUND: Few clinical data are available regarding the effect of Ginkgo biloba extract (EGb 761) on liver microcirculation and fibrosis.
  • This randomized, controlled trial is to investigate the effect of Ginko biloba extract EGb 761 on liver fibrosis and hepatic microcirculation in patients with chronic hepatitis B.
  • METHODS: Sixty-four patients with chronic hepatitis B were randomized for intention-to-treat.
  • Thirty-two patients were assigned to treated group receiving EGb 761 plus polyunsaturated phosphatidylcholine (Essentiale), 32 patients received Essentiale as controls.
  • Blood samples were taken for measurement of transforming growth factor beta-1 (TGF-β1), platelet activate factor (PAF), endothelin 1 (ET-1).
  • Twenty-six patients in treated group and 21 patients in control group underwent liver biopsies for histology before and after treatment.
  • Ultrastructural study for sinusoidal microcirculation before and after treatment was carried out on 10 randomly selected patients in each group.
  • RESULTS: In the treated group, after EGb 761 treatment, there was a significant reduction of blood TGF- β1, PAF and ET-1 (p<0.05), whereas this was not observed in the controls.
  • After treatment in both groups, there were significant decrease of ALT, TBil and PT (p<0.05), and significant increase of ALB (p<0.05).
  • Hepatic inflammation and fibrosis significantly alleviated in the treated group, but not in the controls.
  • After EGb 761 treatment, electron microscopy showed red blood cell aggregates and microthrombosis disappeared or decreased in sinusoids; collagen deposits in sinusoidal lumen and Disse space reduced; sinusoidal capillarization alleviated.
  • CONCLUSIONS: EGb 761 can improve sinusoidal microcirculation, alleviate inflammation and inhibit fibrosis through multiple mechanisms, it is effective in the treatment of chronic liver diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994702.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Chronic Hepatitis B / EGb 761 / Endothelin-1 / Ginko biloba / Hepatic fibrosis / Hepatic microcirculation
  •  go-up   go-down


Advertisement
4. Yoshida T, Saito J, Ichimaru N, Miyagawa Y, Nishimura K, Okuyama A, Tomita H, Aozasa K: [Local recurrence of spermatic cord liposarcoma: a case report]. Hinyokika Kiyo; 2006 Jul;52(7):581-4
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrence of spermatic cord liposarcoma: a case report].
  • A 46-year-old man had undergone radical high orchiectomy because of a tumor of the right spermatic cord.
  • Pathological diagnosis was atypical lipomatous tumor.
  • Local recurrence was suspected, and surgical resection of the tumor with a sufficient surgical margin was performed.
  • Pathological diagnosis was well-differentiated liposarcoma, sclerosing type.
  • Ten cases of recurrent spermatic cord liposarcoma, including the present case, have been reported in Japan.
  • Because of the possibility of local recurrence, spermatic cord liposarcoma needs strict and long-term follow up.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Liposarcoma / surgery. Neoplasm Recurrence, Local / surgery. Orchiectomy. Spermatic Cord

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910596.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Titiz A, Yilmaz YF, Ceyhan S, Unal T: Atypical lipomatous tumor in the submental region. J Craniofac Surg; 2008 Nov;19(6):1558-60
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor in the submental region.
  • A 54-year-old male patient presented to our outpatient clinic complaining of a mass under his chin, which appeared nearly 1 year earlier.
  • Pathologic diagnosis was atypical lipomatous tumor.
  • Atypical lipomatous tumors/well-differentiated liposarcomas are rarely reported in the head and neck.
  • We review the clinical and management features of atypical lipomatous tumors.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Liposarcoma / diagnosis
  • [MeSH-minor] Adipocytes / pathology. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Cell Nucleus / ultrastructure. Contrast Media. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-mdm2 / analysis. S100 Proteins / analysis. Stromal Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098551.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / S100 Proteins; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 13
  •  go-up   go-down


6. Shi HY, Wei LX, Wang HT, Sun L: Clinicopathological features of atypical lipomatous tumors of the laryngopharynx. J Zhejiang Univ Sci B; 2010 Dec;11(12):918-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of atypical lipomatous tumors of the laryngopharynx.
  • Atypical lipomatous tumor (ALT) of the laryngopharynx is rare.
  • Symptoms included dysphagia (2/5), dysphonia (3/5), and the feeling of a foreign body in the throat (5/5).
  • Tumors were well circumscribed or focally infiltrative, ranging from 2.0 to 5.0 cm (median, 3.4 cm) in size, and microscopically showed the typical features of lipoma-like ALT.
  • Immunohistochemically, tumor cells were stained with S-100, vimentin, murine double minute 2 (MDM-2), and cyclin-dependent kinase 4 (CDK4).
  • Two patients had local tumor recurrences at 6 and 14 months after initial surgery during follow-up.
  • ALT of laryngopharynx is an indolent tumor.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Lipoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Apr;190(5):531-6 [10727978.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2009 May;14(5):E252-6 [19218900.001]
  • [Cites] Dysphagia. 2001 Summer;16(3):224-7 [11453572.001]
  • [Cites] J Laryngol Otol. 2001 Jul;115(7):593-5 [11485600.001]
  • [Cites] Emerg Med J. 2002 May;19(3):275 [11971855.001]
  • [Cites] Otolaryngol Pol. 2002;56(6):669-74 [12577479.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):134-41 [2301699.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Jul 15;68(2):85-90 [8353809.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):694-8 [7791904.001]
  • [Cites] Laryngoscope. 1995 Jul;105(7 Pt 1):747-56 [7603280.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):623-30 [8579124.001]
  • [Cites] Australas Radiol. 1996 May;40(2):165-8 [8687353.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):775-9 [8780382.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1182-9 [8827023.001]
  • [Cites] Rev Invest Clin. 1998 May-Jun;50(3):259-61 [9763894.001]
  • [Cites] J Laryngol Otol. 1998 Sep;112(9):880-2 [9876384.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Pathol Res Pract. 1999;195(2):125-8 [10093833.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1999;120(1):39-42 [10371864.001]
  • [Cites] Laryngoscope. 1999 Aug;109(8):1245-52 [10443828.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Jun;116(6):418-24 [17672243.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Mar;109(3):301-5 [10737315.001]
  • (PMID = 21121069.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2997399
  •  go-up   go-down


7. Katenkamp K, Katenkamp D: Soft tissue tumors: new perspectives on classification and diagnosis. Dtsch Arztebl Int; 2009 Sep;106(39):632-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors: new perspectives on classification and diagnosis.
  • BACKGROUND: In recent years, new tumor entities have been described and previously known tumor types have undergone a reassessment.
  • This article offers an overview of recent developments in the classification and interpretation of soft tissue tumors.
  • METHODS: Selective review of publications from 1990 until 2008 from the literature database of the Consultation and Referral Center for Soft Tissue Tumors in Jena.
  • RESULTS: The description of the biological behavior of soft tissue tumors has become more detailed with the introduction of two intermediate categories ("intermediate, locally aggressive" and "intermediate, rarely metastasizing").
  • Previously established terms such as "malignant fibrous histiocytoma" or "hemangiopericytoma" will be used much less often in future, because these tumor types have been reinterpreted.
  • The WHO recommends that highly differentiated liposarcoma be renamed "atypical lipomatous tumor."
  • The importance of molecular tumor characterization for individually tailored therapy is already becoming clear.
  • CONCLUSIONS: Optimal diagnosis is the prerequisite for effective therapy and can be achieved only with state-of-the-art knowledge of the pathology of soft tissue tumors.
  • [MeSH-major] Soft Tissue Neoplasms / classification. Soft Tissue Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3364-71 [18951519.001]
  • [Cites] Cancer. 1977 Apr;39(4):1672-85 [192434.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Histopathology. 2006 Jan;48(1):13-21 [16359533.001]
  • [Cites] Histopathology. 2006 Jan;48(1):63-74 [16359538.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):454-9 [17325488.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1476-89 [17895748.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):743-9 [17701051.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):119-32 [18080139.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):476-89 [18318588.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):354-62 [18300816.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1977 Mar;85A(2):127-40 [15396.001]
  • (PMID = 19890408.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  • [Other-IDs] NLM/ PMC2770206
  • [Keywords] NOTNLM ; biopsy / cancer diagnosis / molecular biology / molecular medicine / soft-tissue sarcoma
  •  go-up   go-down


8. Weaver J, Goldblum JR, Turner S, Tubbs RR, Wang WL, Lazar AJ, Rubin BP: Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol; 2009 Jan;22(1):66-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.
  • Inflammatory liposarcoma is a variant of well-differentiated liposarcoma/atypical lipomatous tumor that consists of a mixture of lymphocytes, histiocytes, scattered atypical stromal cells, mature adipocytes, and rarely lipoblasts.
  • Well-differentiated liposarcoma/atypical lipomatous tumor and dedifferentiated liposarcoma have characteristic molecular markers in the form of giant marker and ring chromosomes consisting of amplicons of 12q13-15, which includes MDM2.
  • MDM2 immunohistochemistry (IHC) (Zymed; clone IF2) and dual color fluorescence in situ hybridization utilizing MDM2 (12q15) and chromosome 12 centromeric probes were performed on formalin-fixed and paraffin-embedded specimens from inflammatory well-differentiated liposarcoma (17 cases), sclerosing mesenteritis (14 cases), and idiopathic retroperitoneal fibrosis (10 cases).
  • MDM2 expression as detected by IHC is a very sensitive tool in recognizing inflammatory well-differentiated liposarcoma (17 of 17); however, 21% (3 of 14) and 10% (1 of 10) of sclerosing mesenteritis and retroperitoneal fibrosis, respectively, displayed weak MDM2 immunoexpression.
  • The MDM2 fluorescence in situ hybridization assay was very specific for inflammatory well-differentiated liposarcoma as 15 of 17 (88%) cases showed MDM2 amplification, whereas none of the cases of sclerosing mesenteritis or idiopathic retroperitoneal fibrosis showed amplification.
  • Increased MDM2 expression and/or MDM2 amplification can be employed to aid discrimination of inflammatory well-differentiated liposarcoma from fibroinflammatory mimics.
  • However, lack of MDM2 immunoexpression would rule out the possibility of inflammatory well-differentiated liposarcoma.
  • [MeSH-major] Biomarkers, Tumor / genetics. Liposarcoma / diagnosis. Panniculitis, Peritoneal / diagnosis. Proto-Oncogene Proteins c-mdm2 / genetics. Retroperitoneal Fibrosis / diagnosis


9. Angeles RM, Vasquez J, Kim O: Pathologic quiz case: an 86-year-old man with a painless right tongue mass. Atypical lipomatous tumor of the tongue. Arch Pathol Lab Med; 2005 Feb;129(2):253-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: an 86-year-old man with a painless right tongue mass. Atypical lipomatous tumor of the tongue.
  • [MeSH-major] Lipoma / diagnosis. Tongue Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679435.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Mahmood U, Nguyen JD, Chang J, Gu M, Wong BJ: Atypical lipomatous tumor/well-differentiated liposarcoma of the parotid gland: case report and literature review. Ear Nose Throat J; 2009 Oct;88(10):E10-6
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor/well-differentiated liposarcoma of the parotid gland: case report and literature review.
  • Although liposarcoma is the second most common soft-tissue sarcoma in adults, it is exceedingly rare in the head and neck.
  • According to our MEDLINE search, only 11 cases of liposarcoma of the parotid gland have been reported since 1968.
  • We report a new case of primary atypical lipomatous tumor/well-differentiated liposarcoma of the parotid gland in a 77-year-old man.
  • Because only a very limited number of case reports and small series have been published on liposarcoma in the head and neck, we also provide a review of the literature on this uncommon disease entity.
  • [MeSH-major] Lipoma / diagnosis. Liposarcoma / diagnosis. Parotid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19826985.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


11. He M, Aisner S, Benevenia J, Patterson F, Aviv H, Hameed M: p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor from deep-seated lipoma. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):51-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor from deep-seated lipoma.
  • Atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDLPS) is a locally aggressive malignant mesenchymal neoplasm, resembling ordinary lipoma in many clinical aspects.
  • Fifty cases of lipomatous neoplasms, with cytogenetic results, from 45 patients were collected from the archives in Department of Pathology, University of Medicine and Dentistry of New Jersey/New Jersey Medical School during 1998 to 2006.
  • These include 18 cases of deep-seated lipoma, 1 hibernoma, 1 lipoblastoma, and 30 cases of ALT/WDLPS. p16 was detected in 25/30 (83.3%) of ALT/WDLPS, and none (0/18) of the deep-seated lipomas (P<0.0000001, Fisher exact test).
  • MDM2 was detected in 18/30 (60%) of ALT/WDLPS, and was negative in 0/18 of the deep-seated lipomas (P<0.0001, Fisher exact test).
  • Combined together, 27/30 (90%) of ALT/WDLPS showed positive staining of either p16, MDM2, or both, whereas no staining was observed in all the deep-seated lipomas (P<0.0000001, Fisher exact test).
  • These results indicated that p16 is yet another marker which seems to be a valuable marker to differentiate ALT/WDLPS from deep-seated lipomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779733.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


12. Nilsson M, Domanski H, Mertens F, Mandahl N: Atypical lipomatous tumor with rare structural rearrangements involving chromosomes 8 and 12. Oncol Rep; 2005 Apr;13(4):649-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor with rare structural rearrangements involving chromosomes 8 and 12.
  • Atypical lipomatous tumor (ALT), an intermediate malignant neoplasm of soft tissues, is characterized by the presence of supernumerary ring and giant marker chromosomes.
  • Whether ALTs with these types of aberrations have a lower risk of tumor progression than ALTs with the notoriously mitotically unstable ring and giant marker chromosomes remains to be investigated.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 8. Lipoma / genetics. Lipoma / pathology. Neoplasms, Adipose Tissue / genetics. Neoplasms, Adipose Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756437.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


13. Debelenko LV, Perez-Atayde AR, Dubois SG, Grier HE, Pai SY, Shamberger RC, Kozakewich HP: p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Pediatr Dev Pathol; 2010 May-Jun;13(3):218-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
  • The spectrum of lipomatous tumors differs in the adult and pediatric populations, with liposarcoma being rare in children.
  • Two atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLS) were identified in the pathology files of our institution in young children from "classical" Li-Fraumeni and Li-Fraumeni variant kindreds with a known germline TP53 mutation (Y220C) in one of the families.
  • The tumors had a high degree of cellular atypia and differed from sporadic ALT/WDLS by strong nuclear immunoreactivity for p53 and absent mdm2 expression.
  • ALT/WDLS in a young child should raise the possibility of a cancer predisposition syndrome and, in this setting, the p53(+)/mdm2(-) immunophenotype might be characteristic.
  • Recognition of this lesion and its association is important for early diagnosis and subsequent tumor surveillance in the proband and affected family members.
  • [MeSH-major] Li-Fraumeni Syndrome / pathology. Lipoma / pathology. Liposarcoma / pathology. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child. Child, Preschool. Family Health. Fatal Outcome. Female. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Male. Pedigree

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Young syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028212.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


14. McQueen C, Montgomery E, Dufour B, Olney MS, Illei PB: Giant hypopharyngeal atypical lipomatous tumor. Adv Anat Pathol; 2010 Jan;17(1):38-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant hypopharyngeal atypical lipomatous tumor.
  • The so-called "giant fibrovascular polyps" of the esophagus and hypopharynx typically present as sausage-like pedunculated structures that protrude into the lumen and cause obstructive symptoms.
  • Microscopically, they display an admixture of fibrovascular and adipose tissue that is coated by unremarkable squamous mucosa.
  • Here, we report a case that had scattered hyperchromatic cells and lipoblasts within the adipose tissue component.
  • In other anatomic sites similar appearing lesions have been interpreted as pedunculated liposarcomas/atypical lipomatous tumors that are more prone to local recurrences than classic giant fibrovascular polyps.
  • To confirm our suspicion of liposarcomatous differentiation, we performed immunohistochemistry for MDM2 and p53, 2 markers that are known to be negative in benign lipomatous lesions and positive in well-differentiated liposarcomas/atypical lipomatous tumors.
  • The scattered atypical hyperchromatic cells and the lipoblasts both exhibited strong nuclear staining for both markers and supported the diagnosis of pedunculated giant hypopharyngeal atypical lipomatous tumor.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Liposarcoma / pathology
  • [MeSH-minor] Humans. Immunohistochemistry. Male. Middle Aged. Polyps / diagnosis. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032637.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 51
  •  go-up   go-down


15. Schmack I, Patel RM, Folpe AL, Wojno T, Zaldivar RA, Balzer B, Kang SJ, Weiss SW, Grossniklaus HE: Subconjunctival herniated orbital fat: A benign adipocytic lesion that may mimic pleomorphic lipoma and atypical lipomatous tumor. Am J Surg Pathol; 2007 Feb;31(2):193-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival herniated orbital fat: A benign adipocytic lesion that may mimic pleomorphic lipoma and atypical lipomatous tumor.
  • Over the past several years, we have seen a number of cases in which this prolapsed fat was confused pathologically with a neoplasm of adipocytic lineage, specifically pleomorphic lipoma and atypical lipomatous neoplasm (well-differentiated liposarcoma).
  • We conclude that subconjunctival herniated orbital fat commonly contains multinucleated floretlike giant cells, fibrous septae, and Lochkern cells, features that may result in diagnostic confusion with pleomorphic lipoma and atypical lipomatous neoplasms.
  • Importantly, specific diagnostic features, such as aggregates of bland spindled cells associated with wiry collagen, as seen in pleomorphic lipoma, and enlarged hyperchromatic cells within fibrous septae, as in atypical lipomatous neoplasms, are entirely absent in herniated orbital fat.
  • [MeSH-major] Adipose Tissue / pathology. Conjunctiva / pathology. Conjunctival Diseases / pathology. Eye Neoplasms / diagnosis. Lipoma / diagnosis. Liposarcoma / diagnosis. Orbit / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255763.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30-EY06360
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


16. Masood AI, Javed AA, Mateen A, Gurchani SA: Concomitant chemoradiation using gemcitabine in locally advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor response was assessed by computed tomography (CT) eight weeks after completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM: Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):10012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were observed, but 2 pts had tumor shrinkage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962524.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Plummer R, Hayward L, Lorigan P, Soriano V, Moiseyenko V, Szyldergemajn S, Prados R, Smyth J, Calvert H: Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). J Clin Oncol; 2009 May 20;27(15_suppl):9059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).
  • : 9059 Background: AUM remains incurable in most patients (pts).
  • DTIC alone had a 8-15% response rate (RR), while plitidepsin (Aplidin [APL]) showed a 6% RR and a 14% stable disease (SD) in a Phase (Ph) II study in 35 relapsed/refractory pts after DTIC failure.
  • Furthermore, APL + DTIC has additive activity in preclinical models.
  • METHODS: This multicenter Ph Ib study aim to determine the safe recommended dose (RD) of APL on days 1, 8 & 15 + DTIC only day 1 q4wk.
  • RD was defined as the highest dose with >5 days G4 neutropenia or G4 thrombocytopenia (TC) and/or febrile neutropenia (FN); any drug-related ≥ G3 toxicity (except nausea/vomiting or hypersensitivity reaction) in cycle 1.
  • RESULTS: Of 28pts with AUM, 23 were evaluable for DLT; 57% were males, median (med) age was 48 y (20-77), med ECOG 0 (0-2) and med LDH was 226 IU/l (126-983).
  • Most pts (96%) had metastasis with a median of 2 sites involved (1-5).
  • Dose levels of APL + DICT (mg/m<sup>2</sup>), were: DL1 (1.8 + 800), 7 pts; DL2 (2.4 + 800), 8 pts; DL 2b (2.4 + 1000), 5 pts; DL3 (3.0 + 800), 8 pts.
  • Pts received 4 (2-6), 2 (2-5), 2 (1-2), 2 (1-8) median cycles respectively.
  • The number of DLTs were 1/6, 1/7, 2/4, 2/6, respectively.
  • DLTs were G3 ALT in 4 pts and FN + TC in 1 pt.
  • The MTD was at DL 2B and the RD was at DL 2.
  • There were 3 partial responses (PR, 14%) and 4 SD > 3 months (19%); all PR at DL2/3.
  • Five pts were not evaluable, 2 pts had G3 hypersensitivity reactions related to Cremophor oil (APL formulation) and 1 pt had a idiosyncratic reaction to DTIC with prolonged pancytopenia.
  • One pt had a wrong diagnosis and 1 pt had early progressive disease (PD).
  • CONCLUSIONS: APL + DTIC can be safely combined at ≥ 70% of their respective single- agent RD in AUM.
  • Main DLTs were asymptomatic, transient and reversible ALT elevations.
  • Ph Ib showed 14 % PR and 19% clinically meaningful SD.
  • A randomised Ph II study of DTIC + APL vs APL alone is ongoing.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962154.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P: A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol; 2009 May 20;27(15_suppl):2047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At least 1 post-baseline tumor assessment at 4 weeks was available for 26 pts.
  • Based on investigator assessment of bidimensional contrast-enhancing tumor measurements, 10 pts (38%) had a best radiologic response of >= 50% reduction from baseline (including 1 pt with a 100% reduction), 9 pts (35%) had tumor measurement changes ranging from +24% and -49%, and 7 pts (27%) had a >= 25% increase in tumor burden.
  • Of the 17 anti-angiogenic-naïve pts, 9 (53%) had a best radiologic response of >= 50% reduction in tumor burden.
  • CONCLUSIONS: XL184 at a dose of 175 mg PO qd, has demonstrated substantial activity in pts with progressive or recurrent GBM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964644.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nakagawa K, Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Kiriyama T: Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST). J Clin Oncol; 2009 May 20;27(15_suppl):e14630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A standard "3+3" design was employed in both treatment schedules and treatment continued until tumor progression or dose-limiting toxicity (DLT) was observed.
  • One pt with NSCLC had a documented PR with cavity formation inside the tumor.
  • CONCLUSIONS: SU 37.5 mg/day (CDD schedule) plus Pem 500mg/m<sup>2</sup> every 21 days, and SU 50 mg/day (S-2/1 schedule) plus Pem 500mg/m<sup>2</sup> every 21 days were well tolerated and associated with encouraging antitumor activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964182.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Filipponi F, Bartolozzi C, Del Tacca M, Ricci S: A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. J Clin Oncol; 2009 May 20;27(15_suppl):4592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour response was assessed according to RECIST criteria every 9 weeks.
  • The S+5FU association is feasible, well tolerated and AEs were predictable and manageable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV: Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol; 2009 May 20;27(15_suppl):4578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase in adjusted post- to pre-treatment SUV increased the risk for tumor progression (hazard ratio=3.054).
  • FDG-PET showed significant early decreases in SUVmax following treatment, and these changes correlated with tumor response and time to tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • Pts with ≥ 25% tumor shrinkage continued treatment with AV-951, while pts with < 25% change from baseline were randomly assigned to receive AV-951 or placebo for 12 wks (double-blinded).
  • The AE profile of AV-951 is consistent with that of a selective VEGFR inhibitor, with minimal off-target toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: SCH 66336 in combination with TMZ is well-tolerated and shows promising response when administered to patient when stable on TMZ alone or after RT and TMZ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Drullinsky P, Fornier MN, Sugarman S, D'Andrea G, Troso-Sandoval T, Seidman AD, Yuan J, Patil S, Norton L, Hudis C: Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer.
  • : 590 Background: CMF (C 600 mg/m<sup>2</sup>, M 40 mg/m<sup>2</sup>, F 600 mg/m<sup>2</sup>) is an option for adjuvant therapy for patients with low risk early stage breast cancer.
  • DD regimens as predicted by mathematical models of cancer growth and treatment response are superior.
  • We previously demonstrated the safety of DD EC (epirubicin/cyclophosphamide) followed by paclitaxel at 10-11 day (d) intervals.
  • We investigated the feasibility of administering DD adjuvant CMF every 14 d and then every 10-11 d in a 2-stage phase II trial.
  • METHODS: An initial cohort (A) was treated q 14 d with PEG-filgrastim (Neulasta) support.
  • A second cohort (B) was treated every 10-11 d with filgrastim/Neupogen x 5 d and then, based on feasibility, modified (cohort C) to use 7 d filgrastim.
  • The primary end point was feasibility defined as having ANC > 1.5 x 10<sup>3</sup>/uL on day 1 of planned treatment for all 8 cycles with no grade 3 or higher non-hematologic toxicity.
  • All three cohorts were tested using a Simon's two-stage optimal design with type I and type II errors set at 10%.
  • This design would effectively discriminate between true tolerability (as protocol-defined) rates of< 60% and> 80%.
  • Cohort A: 38 pts with early stage breast cancer were accrued from 3/2008 though 6/2008.
  • Cohort B: 7 pts were accrued from June 2008 through August 2008.
  • Cohort C: Is still open with 16 pts accrued from August 2008 through December 5, 2008.
  • RESULTS: Median age 51: range 38 to 78.
  • Cohort A: 29/38 pts completed 8 cycles of CMF.
  • The regimen was considered feasible.
  • 2 other pts completed 7 cycles and were withdrawn for depression and grade 2 transaminitis.
  • The 7 other pts completed between 1 and 6 cycles of CMF were withdrawn as follows: 3 personal, 1 (grade 3) bone pain, 2 allergy unrelated to CMF, and 1 seizure.
  • Cohort B: 7 pts were accrued.
  • 6 out of 7 pts could not complete 8 cycles of chemotherapy secondary to neutropenia and 1 secondary to grade 3 ALT elevation.
  • Cohort C: Accrual has not been completed.
  • 16 pts are currently enrolled.
  • CONCLUSIONS: Dose dense adjuvant CMF is feasible at 14 d intervals with PEG-filgrastim support.
  • Adjuvant CMF every 10-11 days with filgrastim given for 5 days beginning day 2 is not feasible.
  • Accrual is ongoing for CMF at 10-11 days with filgrastim x 7 days.
  • Updated results will be available for Cohort C.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Frentzas SN, Groves MD, Barriuso J, Harris D, Reardon D, Curtis MC, Suttle AB, Ma B, Lager JJ, de Bono JS: Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):2040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • CONCLUSIONS: High dose radiotherapy and concurrent FDR-G, utilizing the techniques above, is well tolerated and results in highly encouraging response rates, local control rates and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • Initial trials of the oral, pan-Bcl-2 inhibitor AT-101 showed acute dose limiting toxicity of Gr 3-4 AST/ALT (MTD 40 mg/d) and ileus with prolonged dosing daily (QD) for 21/28 days per cycle (Saleh, NCI/EORTC, 2005; James, ASCO, 2006 and Saleh, ASCO, 2007).
  • MTD in the QD schedule has been previously reported.
  • In this study different dosing schedules of AT-101 were tested in adults with advanced cancers and final results for the pulse dosing schedule of twice a day for three days every other week (b.i.d. x 3d EOW) are being reported.
  • METHODS: Serial patient (pt) cohorts received AT-101 at escalating doses of 30-80 mg b.i.d. x 3d EOW.
  • Adverse events (AEs) were graded by the NCI CTCAE v3.0.
  • Efficacy was determined by RECIST.
  • RESULTS: 37 pts have been enrolled.
  • Safety data is available on 34/37 pts.
  • In this b.i.d. x 3d EOW dosing schedule, ileus/small bowel obstruction (SBO) occurred in 3 pts (one at each dose level of 30, 40 and 50 mg) and was the dose limiting toxicity for this schedule.
  • Of note, the SBO that occurred at 30 mg was felt to be unrelated to study agent therefore, 30 mg b.i.d. x 3d EOW was the MTD determined for this schedule.
  • The most common (>50%) grade 1-2 AEs included: nausea, vomiting, diarrhea, fatigue and anorexia.
  • Grade 3-4 AEs occurring in > 2 pts include: nausea, abdominal pain, elevated AST (3 pts each), vomiting, fatigue, dehydration (4 pts each), hypokalemia (5 pts).
  • Stable disease was reported in 13/37 (35%) pts.
  • One pt with NSCLC continues on study with stable disease for 33 cycles and 2 additional pts were on study with stable disease for 18 and 9 cycles.
  • The mean Plasma C<sub>max</sub> was 301 ng/ml (+ 477 ng/ml SD) and mean AUC for 30 mg b.i.d.x3d EOW was 1080 ng*hr/ml (+ 1990 ng/ml SD) with a median peak concentration at 4 hours post dose.
  • CONCLUSIONS: Pulse dosing of AT-101 achieved an MTD of 30mg b.i.d. x 3d EOW and is associated with reduced toxicity than continuous daily dosing, and may be preferable in combination regimens.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K: A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503. J Clin Oncol; 2009 May 20;27(15_suppl):7561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503.
  • : 7561 Background: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC.
  • However, the optimum chemotherapy regimen has not been determined.
  • TORG 0503 was conducted to evaluate platinum-based third generation regimens in this clinical setting.
  • METHODS: Patients with completely resected stage IB, IIA, IIB or stage IIIA NSCLC were stratified by stage (IB/IIA vs. IIB/IIIA) and institution and randomized to receive 3 cycles of DOC (60 mg/m2, day 1) plus CIS (80 mg/m2, day 1) or 3 cycles of PAC (200 mg/m2, day 1) plus CAR (AUC 6, day 1).
  • Both regimens were repeated every 3 - 4 weeks.
  • Other eligibility criteria included ECOG PS 0-1, age ≥20, and =<70 years old, adequate organ function, no prior chemotherapy or radiotherapy.
  • Patients who underwent pneumonectomy were excluded.
  • The primary endpoint was 2-year relapse free survival (RFS), and secondary endpoints were overall survival (OS), quality of life (QOL), feasibility and toxicity.
  • RESULTS: 111 patients were randomized between April 2006 and July 2008, 58 patients to DOC+CIS (DC) and 53 to PAC+CAR (PA).
  • Patients' demographics (DC/PA): median age 63/59 years, 60%/66% male, 17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% of patients were stage IB/IIA, 60%/60% IIB/IIIA.
  • Feasibility: 93% (54/58) of patients allocated to DC and 92% (49/53) patients in the PA arm completed 3 planned cycles of chemotherapy.
  • Toxicities: DC vs.
  • PA: Grade (G) 3/4 neutropenia (86%/75%), G3/4 anemia (2%/0%).
  • G 3 febrile neutropenia (10%/4%), G2 ALT (0%/10%), G2 creatinine (17%/0%), G2-4 allergy (0%/4%), G2 alopecia (43%/47%), G2/3 fatigue (5%/10%), G2/3 anorexia (43%/22%), G2/3 nausea (47%/22%), G2/3 vomiting (31%/12%), G2 diarrhea (12%/8%), G2 constipation (2%/4%), G2/3 sensory neuropathy (3%/33%), G2/3 arthralgia (0%/31%), G2 myalgia (2%/8%).
  • No treatment related deaths were observed in either arm.
  • CONCLUSIONS: Both docetaxel plus cisplatin and paclitaxel plus carboplatin are safe and feasible regimens as adjuvant chemotherapy.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Okusaka T, Kasugai H, Ishii H, SM-11355 Japan Study Group: A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with unresectable HCC were randomized 2:1 to receive an injection of SM-11355 or zinostatin stimalamer suspended in lipiodol into the hepatic artery at doses of up to 6 mL (SM-11355: 120 mg; zinostatin stimalamer: 6 mg) according to the tumor size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963097.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Chen L, Shiah HS, Chen CY, Lin YJ, Lin PW, Su WC, Chang JY: Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up-regulation of mTOR expression has been noted in 40-45% of HCC, and preclinical studies suggest mTOR inhibitor can effectively inhibit proliferation of HCC cells as well as growth of HCC xenograft in mice.
  • RESULTS: A total of 36 pts (M/F 34/2; median age 58.5, range 28-75; Child-Pugh's class of A/B 31/5) were enrolled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were evaluable for safety and survival and twenty seven patients (79.4%) were evaluable for tumor response.
  • CONCLUSIONS: This results showed that the combination chemotherapy with irinotecan, 5-FU and leucovorin was well tolerated and active in taxane and cisplatin refractory patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Tiersten A, Sill M, Muggia F, Elera C, Garcia A, Fracasso P, Swensen R, Warshal D, Mannel R, Gynecologic Oncology Group: Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol; 2009 May 20;27(15_suppl):5544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study.
  • : 5544 Background: Dose-dense regimens improve outcome for women with breast cancer.
  • We investigated the feasibility of dose-dense CP for women with ovarian cancer.
  • METHODS: Pts with untreated stage III/IV ovarian cancer received C AUC 5 and P 175 mg/m2 day 1, pegfilgrastim 6 mg day 2 every 2 weeks for 6 cycles.
  • Dose-limiting toxicity (DLT) was defined as: febrile neutropenia, grade 4 neutropenia ≥7 days, grade 4 thrombocytopenia (tcp), grade 3 tcp with bleeding, dose delay >2 weeks, grade 3/4 non-hematologic toxicity (excluding fatigue, hypersensitivity, nausea/vomiting, alopecia, constipation, diarrhea or bone pain), and any treatment related death.
  • The study utilized a 2-stage sequential design (20 pts/stage) with DLTs in 6 cycles determining regimen feasibility.
  • RESULTS: Between September 2006 and September 2008, 43 pts enrolled.
  • Twenty and 17 patients were evaluable for toxicity over 6 cycles in stages 1 and 2 respectively.
  • Six DLT's were observed for both stages.
  • Thirty pts completed treatment and 12 did not [DLTs (6), paclitaxel hypersensitivity reactions (2), progression (1), patient choice (1), infection (1) and death unrelated to treatment (1)].
  • One pt remains on treatment.
  • The 6 DLTs resulting in treatment discontinuation included grade 3 neuropathy (2), grade 4 neuropathy (1), grade 4 tcp (1), grade 4 tcp/grade 3 febrile neutropenia (1), and grade 4 SVT (1).
  • Six other DLTs not preventing treatment completion included grade 3 infection (1), grade 3 AST/ALT elevation (1), grade 3 confusion (1), grade 3 dehydration (1), grade 3 neuropathy (1) and grade 4 tcp (1).
  • Other toxicities resulting in treatment delays included grade 3 tcp (1), grade 3 fatigue (1) and grade 2 neuropathy (2).
  • There were 5 P dose reductions and 4 C dose reductions.
  • CONCLUSIONS: Seventy-two percent pts completed 6 cycles of dose-dense CP.
  • Based on DLTs (at least 12 in 37 evaluable pts), this regimen is not feasible.
  • Given the neuropathy and tcp, we do not recommend further investigation in a phase III trial.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.
  • : e15506 Background: Dasatinib (D) is a small molecule tyrosine kinase inhibitor with activity against both bcr-abl and src.
  • Cetuximab (C) is a monoclonal antibody that blocks EGFR.
  • Preclinical models suggest D reverses resistance to G.
  • In addition, src and EGFR pathways interact; synergism of dual blockade by D + C is possible.
  • We evaluated two combination regimens, GD and GDC, in a Phase I dose escalation study.
  • METHODS: Patients (pts) with advanced solid tumors were enrolled in cohorts of 3-6 to either GD or GDC.
  • G was dosed in mg/m<sup>2</sup> weekly for 3 of 4 weeks, D was dosed in mg PO BID, and C was dosed at 250 mg/m<sup>2</sup> weekly after loading dose of C=400; cycle length was 28 days.
  • Dose levels were as follows:.
  • 1) G 1000 + D 50 ± C;.
  • 2) G 1,000 + D 70 ± C;.
  • 3) G 1,000 + D 100 ± C.
  • Standard cycle 1 DLT definitions were used.
  • Eligible pts had advanced solid tumors, adequate organ and marrow function, and no co-morbidities that would increase risk of toxicity.
  • Serum, plasma, and skin biopsy biomarkers were obtained pre- and on treatment.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • Four DLT were observed: Gr 3 ANC with infection (GDC1, n=1), Gr 3 ALT (GD2, n=2), and Gr 5 pneumonitis (GDC2, n=1).
  • Possible treatment-related adverse events in later cycles included: Gr3-4 ANC (n=4), Gr4 colitis (n=1), Gr3 bilirubin (n=2), Gr3 Hgb (n=2), Gr3 Plt (n=2), Gr3 edema/fluid retention syndrome (n=1), and Gr3 vomiting (n=2).
  • One previously untreated pt had a partial response.
  • Eight of 18 pts, 3 of whom had received prior G, had stable disease as best response, median duration = 5 months (range 1-7).
  • Biomarker results are pending.
  • CONCLUSIONS: The MTD of the GD arm is G1000/D50BID.
  • Stable disease in previous G-refractory pts was noted.
  • Hematologic toxicities were dose-limiting; later toxicities including hematologic, LFT changes, pneumonitis, and fluid retention were seen.
  • To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Saltz L, Infante J, Schwartzberg L, Stephenson J, Rocha-Lima C, Galimi F, Dillingham K, Hsu M, Wiezorek J, Fuchs C: Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):4079

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMG 655 activates caspases and induces apoptosis in sensitive tumor cells.
  • Best overall tumor response: 5 partial responses (2 unconfirmed, both underwent resection); 6 stable disease; 1 pt had non-measurable disease at baseline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its unique antitumor properties, attributed to specific binding to the small groove of DNA, have been demonstrated activity against soft-tissue sarcoma (STS), ovarian, breast and prostate cancer.
  • CONCLUSIONS: Single-agent trabectedin was reasonably well tolerated, with low rates of drug-related discontinuations and deaths.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Ninan JA, Bailey H, Kolesar J, Marnocha R, Eickhoff J, Wright J, Espinoza-Delgado I, Alberti D, Wilding G, Schelman W: A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2531 Background: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an oral histone deacytlase (HDAC) inhibitor that has anti-tumor activity in hematologic malignancies and advanced solid tumors.
  • The treatment plan initially consisted of vorinostat given orally twice daily on days 1-14 with bortezomib IV on days 1, 4, 8, and 11 of a 21 day cycle.
  • Tumor types include: Prostate (1), Colorectal (3), Pancreatic (6), Sarcoma (7), Biliary (1), Thymus (1), GIST (2), Mesothelioma (1), ovarian (1), Neuroendocrine (1), Lung (1), Head and Neck (1), Breast (2), and Cervical (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961857.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Yukawa H, Noguchi H, Oishi K, Takagi S, Hamaguchi M, Hamajima N, Hayashi S: Cell Transplantation of Adipose Tissue-Derived Stem Cells in Combination with Heparin Attenuated Acute Liver Failure in Mice. Cell Transplant; 2009 May/Jun;18(5-6):611-618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell Transplantation of Adipose Tissue-Derived Stem Cells in Combination with Heparin Attenuated Acute Liver Failure in Mice.
  • The effect of adipose tissue-derived stem cells (ASCs) in combination with heparin transplantation on acute liver failure mice with carbon tetrachloride (CCl<sub>4</sub>) injection was investigated.
  • CCl<sub>4</sub> is a well-known hepatotoxin and induces hepatic necrosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880629.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute liver failure / Adipose tissue-derived stem cells (ASCs) / Cell transplantation / Heparin
  •  go-up   go-down


41. Conley AP, Araujo D, Ludwig J, Ravi V, Samuels BL, Choi H, Thall PF, Patel S, Benjamin R, Trent J: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Chan SL, Mo FK, Koh J, Hui EP, Yu SC, Lai PB, Chan HL, Chan VT, Chan AT, Yeo W, Mok T: Predictors of treatment outcomes in early stage hepatocellular carcinoma (HCC) detected in a surveillance program. J Clin Oncol; 2009 May 20;27(15_suppl):4584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4584 Background: Surveillance for HCC in hepatitis B virus (HBV) carriers aims to improve survival by detection of early resectable tumor.
  • Fifty seven pts (54.3%) had solitary tumor but only 34 (32.4%) are amenable to resection.
  • Absence of cirrhosis (p=0.0072) and normal albumin level (p=0.0379) are predictors of surgical resection while tumor size and number are not.
  • Liver function is more important than tumor characteristics in determining the outcome of HCC detected in the surveillance program.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963096.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Elser C, Hirte H, Kaizer L, Mackay H, Bindra S, Tinker L, MacAlpine K, Wang L, Sidor C, Oza A: Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was tumor response by RECIST or CA-125.
  • CONCLUSIONS: MKC-1 was well tolerated in both patient populations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962602.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Hanna NH, Estes D, Arnott J, Marcotte S, Hannah A, Sidor CF, West H, Clamon G, Hoang T: Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 19 phase 2 pts, 18 were evaluable for tumor response.
  • The combination is well tolerated with 17% of patients achieving a confirmed PR thus far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962522.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5 of the 7 BRAF V600E+ pts treated at ≥ 240 mg BID had tumor regression, up to 83%, with 1 confirmed partial response (PR) and 1 unconfirmed PR (too early); 2 of 4 pts with unknown V600E status had tumor regression, up to 50%, with 1 confirmed PR; 2 BRAF wild-type pts had progressive disease.
  • All 7 pts with tumor regression remain progression-free, ranging from 4 to 14 months.
  • 3 thyroid cancer pts with V600E mutations have tumor regression (range 9-16%) and are progression-free (4-7 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R: ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol; 2009 May 20;27(15_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients (pts) were dosed on days 1-14 of a 21 d cycle, 10-440mg (M06-814) or 10-250mg (M06-873).
  • Dose limiting toxicities, 14/21 d dosing, in M06-814 occurred at 160mg (bronchitis), 315mg (elevated ALT and grade 4 TCP) and 440mg (worsening pleural effusion in a pt with underlying afib), and in M06-873 at 110mg (tumor lysis and grade 4 TCP) and 250mg (grade 4 TCP).
  • CONCLUSIONS: ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Traina TA, Theodoulou M, Feigin K, Patil S, Geneus S, Modi S, Fornier M, Lake D, Norton L, Hudis C: Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab.
  • Median (med) age 64 yrs (42-71), med ECOG PS 1 (0-1), ER/PR(+) 3, HER-2(+) 6, sites of MBC: bone (2), viscera (4), soft tissue (5).
  • CONCLUSIONS: Capecitabine (7 - 7) + lapatinib appears well tolerated compared to C(14 - 7)+L (Geyer et al).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Yoshimatsu K, Yokomizo H, Otani T, Osawa G, Ogawa K: Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study regimen is that oral administration of S-1 at 40 mg b.i.d. for 21 consecutive days followed by a 7-day rest period and intravenous infusion of CPT-11 at a dose of 80 mg on days 1 and 15 are performed with weekly subcutaneous injection of peptide vaccine.
  • CONCLUSIONS: Treatment with peptide vaccine and S-1/CPT-11 CT was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kang D, Wang E, Wang D, Amantea M, Hsyu P: Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):3048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma.
  • : 3048 Background: Tremelimumab is a fully human monoclonal antibody targeted against CTLA4, a protein on T cells critical for regulating T-cell activities, which is under development for treatment of various cancers, including melanoma.
  • Population PK analysis was conducted using concentration-time data from 450 pts, most with melanoma or solid tumors, enrolled in four phase I or II studies that evaluated PK, tolerability, and efficacy of single-agent tremelimumab.
  • METHODS: Tremelimumab was administered intravenously either as single dose or multiple doses every 4 or 12 weeks; doses varied between 0.01 and 15 mg/kg.
  • PK was determined using nonlinear mixed-effect modeling implemented in NONMEM VI.
  • Baseline characteristics, including body weight, ECOG score, age, sex, serum creatinine, AST, ALT, and bilirubin, and formulation effects were investigated as potential factors affecting PK.
  • Tremelimumab plasma concentrations were determined using a sensitive, specific, validated ELISA assay.
  • RESULTS: A two-compartment linear model adequately described tremelimumab concentration-time data; an additive residual error model was employed on log-transformed data.
  • Initial and terminal half-lives were 2.5 days and 22 days, respectively.
  • Estimated parameter values were: 0.0109 L/hr for CL (clearance), 3.72 L for V1 (central volume of distribution), 0.0172 L/hr for Q (intercompartment clearance), and 3.31 L for V2 (peripheral volume of distribution).
  • Females had 29.6% smaller V2 compared with males.
  • Both CL and central V1 increased with weight.
  • An ECOG score of ≥1 showed 20.2% increase in CL compared with a score of 0.
  • New commercial formulation decreased CL by 18.5%.
  • The model-predicted area under concentration-time curve value in females was 13.3% greater than males (p=0.5).
  • None of the other covariates tested significantly affected PK.
  • Furthermore, tremelimumab was tolerated in most pts at all doses tested.
  • CONCLUSIONS: PK of tremelimumab were shown to be affected by weight, baseline ECOG score, and formulation.
  • However, no effects other than weight were considered clinically significant enough to warrant treatment regimen change.
  • Further investigation of PK-response relationships is warranted.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabeck C, Root H, Figg WD, Bernstein W: A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PBMCs as well as optional tumor biopsies were collected for Akt inhibition and expression of markers of ER stress (ERS).
  • Tumor types included NSCLC (3), SCLC (2), thyroid (3), pancreatic (1), colorectal (1), and renal cell (1).
  • CONCLUSIONS: N appears to be well tolerated in subjects with advanced solid tumors at 2.5 times the FDA approved dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Takahashi T, Yamamoto N, Murakami H, Ohe Y, Kunitoh H, Nokihara H, Koshiji M, Tamura T: A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):2572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2572 Background: Enz is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through PKC and PI-3 kinase/AKT.
  • CONCLUSIONS: Both schedules of Enz in combination with Pem are well tolerated and clinically active in pts with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Koolen S, Witteveen PO, Garcia-Ribas I, Callies S, Andre V, Kronemeijer RH, Nol A, Beijnen JH, Voest EE, Schellens JH: Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors.
  • : 2576 Background: LY2334737 (LY) is an orally available valproic acid prodrug of gemcitabine that was developed to overcome the extensive first-pass metabolism of gemcitabine to 2',2'-difluorodeoxyuridine (dFdU).
  • The objectives of this study were to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and pharmacokinetics (PK) of LY as monotherapy and in combination with erlotinib.
  • METHODS: Eligible pts had ECOG PS < 2 and adequate hematologic, renal and hepatic function.
  • In Arm A, LY was given daily for 14 days in a 3-week cycle.
  • Pts assigned to Arm B also received erlotinib daily 100 mg continuously.
  • Dose escalation was based on observed toxicity and the modified continual reassessment method (mCRM).
  • The dose was maximally increased by 100% depending on the toxicity observed in the previous cohort.
  • PK of LY, gemcitabine, dFdU and intracellular metabolites were determined.
  • RESULTS: 33 pts (21 m, 12 f, median age 60 yrs (range 24-81)) were treated at 5 different dose-levels (range 5-50 mg/day).
  • Pts received a median of 3 cycles (range 2-17).
  • Three out of 7 pt treated with 50 mg experienced 5 dose limiting toxicities (DLT).
  • DLTs observed at 40 and 50 mg include fatigue (4 pt), thrombocytopenia (1 pt), GGT elevation (1 pt), AST/ALT elevation (1 pt), fever (1 pt), and pulmonary embolism (1 pt).
  • One death was possibly related to LY intake.
  • This pt, treated with 40 mg LY, developed on day 15 dyspnea, hypovolemic shock, and suddenly died.
  • No grade 3 or 4 toxicities were reported at dose-levels < 40 mg.
  • The most common adverse events were fatigue, vomiting, nausea, pyrexia, anorexia, and diarrhea.
  • Two pts with mesothelioma were stable for > 9 months.
  • One pt with refractory prostate cancer presented a PSA CR as assessed by investigator.
  • The PK show dose-proportional increase in exposure of both LY and gemcitabine.
  • Both LY and gemcitabine are rapidly cleared, thus no accumulation occurs.
  • The metabolite dFdU accumulates due to its long half life.
  • CONCLUSIONS: LY displays linear PK.
  • The dose level of 50-mg is non-tolerable and 40-mg is being confirmed as the MTD as single agent and in combination with 100 mg erlotinib.
  • Antitumor activity warrants further development.
  • Pt accrual is ongoing.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961892.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M: Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: AR-67 was infused over 1 hour for 5 days of a 21-day cycle using an accelerated titration phase I trial design.
  • Tumor types included: colorectal (8), non-small cell lung (NSCLC) (4), small cell lung (3), soft tissue sarcoma, (3), head and neck (2), prostate (2), and other (4).
  • The RP2D is 7.5 mg/m<sup>2</sup>/day for 5 days of a 21-day cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A: Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies.
  • : 3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells.
  • KX2-391 has a much wider spectrum of solid tumor activity in vitro, and is more potent in mouse xenografts, as compared to other multikinase Src/Abl inhibitors.
  • CONCLUSIONS: KX2-391 has a favorable PK profile, is well-tolerated, demonstrates preliminary evidence of biologic activity and should be further evaluated in Phase II trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, Solomon B, Bang Y, Ou S, Salgia R: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol; 2009 May 20;27(15_suppl):3509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included colorectal, pancreatic, sarcoma, ALCL and NSCLC.
  • There has been 1 confirmed PR in a sarcoma pt with ALK rearrangement (inflammatory myofibroblastic tumor).
  • Among 10 NSCLC pts whose tumors harbor EML4-ALK rearrangement, 1 pt has had a PR, 2 pts have achieved unconfirmed PR and 4 pts have had SD (3 have experienced reduction in tumor burden by ∼20% in measurable lesions and 1 has been treated for 28 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gomez HL, Philco M, Castaneda C, Pimentel P, Escandon R, Seroogy J, Saikali K, Wolff A, Conlan M: A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol; 2009 May 20;27(15_suppl):1077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Ispinesib appears to be well tolerated on a q14d dosing schedule at doses tested to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Delaloge S, Tedesco KL, Blum J, Gonçalves A, Lubinski J, Efrat N, Osborne C, Lebedinsky C, Tercero JC, Holmes FA: Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):1010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T has EMEA authorization in soft tissue sarcoma after failure of standard treatment.
  • Endpoints were objective response (OR) rate by RECIST, duration of response, progression free survival (PFS), tumor volume changes, safety and exploratory pharmacogenomics (PGx).
  • Tissue samples from 36 pts were collected for RNA expression analysis (XPG + ERCC1 + BRCA1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960738.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Yau CC, Chen PJ, Curtis CM, Murphy PS, Suttle AB, Arumugham T, Hodge JP, Dar MM, Poon R: A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):3561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCC is a highly vascular tumor with increased levels of angiogenic factors including VEGF and VEGFR.
  • DCE- MRI was performed to assess changes in tumor permeability.
  • Median % change in tumor permeability (K<sup>trans</sup>) following 3 weeks of pazopanib administration at the MTD (5 pts) was 45%.
  • Changes in tumor DCE-MRI parameters were seen following repeated dose pazopanib administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Qin S, Yang T, Tak W, Yu S, Tsao C, Kim J, Burock K, Zou J, Voliotis D, Cheng A: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levels. J Clin Oncol; 2009 May 20;27(15_suppl):4590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic function influences treatment as a measure of organ damage and tumor stage.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Mielczarek M, Chrzanowska A, Scibior D, Skwarek A, Ashamiss F, Lewandowska K, Baranczyk-Kuzma A: Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases. Int J Biol Markers; 2006 Jan - Mar;21(1):40-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The studies were conducted on blood serum from 85 patients with CRCLM obtained one to two days before tumor resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207092.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


61. Hawkins RE, Hong SJ, Ulys A, Rolski J, Hong B, Sternberg C: An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC).
  • : 5110 Background: The efficacy and safety of pazopanib (paz), a multikinase angiogenesis inhibitor, was evaluated in a randomized, double-blind placebo-controlled phase III study (VEG105192), in treatment-naïve and cytokine-pretreated patients (pts) with advanced RCC.
  • Pts with progressive disease (PD) on placebo had the option to receive paz 800 mg QD via an extension study (VEG107769).
  • METHODS: Pts with ECOG PS ≤ 2, adequate organ function and no other systemic anticancer treatment since PD on VEG105192 were eligible.
  • The primary endpoint was safety.
  • Secondary endpoints included response rate (RR) per RECIST and progression-free survival (PFS).
  • RR was described along with 95% confidence intervals (CIs).
  • PFS was summarized descriptively using Kaplan-Meier estimates for the median, quartiles and PFS rates at 6, 12, and 18 mo along with approximate 95% CIs.
  • RESULTS: 70 placebo pts were enrolled (+ 1 paz pt as an exemption due to symptom improvement).
  • 34 pts (48%) were treatment-naïve and 37 (52%) were cytokine pretreated (at baseline in VEG105192).
  • Median age was 59 y (25-80); baseline ECOG PS 0 (32%), 1 (52%), and 2 (14%).
  • Median time from randomization to placebo in VEG105192 to start of paz treatment on VEG107769 was 6.4 mo (1-18 mo).
  • At VEG107769 clinical cut-off (May 08), 21 (30%) pts had died, 40 (56%) pts had discontinued paz, and 31 (44%) pts were still on paz.
  • Median exposure to paz was 5.7 mo.
  • Most pts died or discontinued paz due to PD.
  • The majority of adverse events (AEs) were Gr 1/2.
  • Gr 3/4 AEs were experienced by 21%/7% of pts.
  • The most common AEs were hypertension (46%; 4% Gr 3/4), hair color changes (39%; 0% Gr 3/4), diarrhea (38%; 1% Gr 3/4), anorexia (24%; 1% Gr 3/4), and nausea (24%; 0% Gr 3/4).
  • Two pts had fatal AEs: sudden death and gastrointestinal hemorrhage.
  • The most common Gr 3 chemistry laboratory abnormalities were hyponatremia (7%) and elevated ALT (7%) and AST (6%); no Gr 4.
  • RR was 32.4% (95% CI: 21.5, 43.3); median PFS was 8.3 mo (95% CI: 6.1, 11.4 mo).
  • CONCLUSIONS: Patients with advanced RCC who developed PD on placebo in a phase III study subsequently achieved clinical benefit from paz treatment in this extension study.
  • These findings support the continued evaluation of paz in advanced RCC.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Maruyama K, Motoyama S, Okuyama M, Sasaki K, Sato Y, Hayashi K, Nanjo H, Ogawa J: Cervical approach for resection of a pedunculated giant atypical lipomatous tumor of the esophagus. Surg Today; 2007;37(2):173-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical approach for resection of a pedunculated giant atypical lipomatous tumor of the esophagus.
  • We describe how we removed a giant pedunculated atypical lipomatous tumor, arising in the cervical to upper thoracic esophagus and occupying a region extending from the cervical to the middle thoracic esophagus, through a cervical esophagotomy without thoracotomy or laparotomy.
  • We suggest that if the base of the tumor is located in the cervical portion of the esophagus, and if the tumor is not aggressive, the cervical approach is best, irrespective of the size of the tumor.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Liposarcoma / surgery. Neck / surgery. Thoracotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243042.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Kuhnen C, Mentzel T, Lehnhardt M, Homann HH, Sciot R, Debiec-Rychter M: [Lipoma and atypical lipomatous tumor within the same neoplasia: Evidence for a continuous transition]. Pathologe; 2010 Mar;31(2):129-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lipoma and atypical lipomatous tumor within the same neoplasia: Evidence for a continuous transition].
  • [Transliterated title] Lipom und atypischer lipomatöser Tumor innerhalb einer Neoplasie: Hinweis für einen kontinuierlichen Ubergang.
  • The case of a lipomatous tumor with a predominant lipoma component and transition to an atypical lipomatous tumor is presented.
  • A deep-seated soft tissue tumor of the right thigh with a maximum size of 14 cm was resected in a 70-year-old female patient.
  • Corresponding to a comparable macroscopic aspect, the lesion revealed the histological features of an ordinary lipoma without atypia in about 80% of the specimen.
  • In the remaining portion (approximately 20%) histopathology showed an atypical lipomatous tumor (ALT, lipoma-like subtype).
  • Immunohistochemistry for MDM 2 and CDK4 revealed no immunoreactivity in the lipoma component, but within the ALT component.
  • Interphase dual-color fluorescence in situ hybridization showed no amplification of the MDM 2 gene and rarely CDK4 gene amplification within the lipoma component, but high level amplification of MDM 2/CDK4 gene in the ALT area, further supporting the morphologically based diagnosis of a lipomatous tumor including areas of a true lipoma and ALT.
  • This case underlines the concept of a continuous stepwise development of lipomatous soft tissue tumors from benign to malignant counterparts as a biological continuum.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lipoma / pathology. Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase 4 / genetics. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-mdm2 / genetics. Thigh

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063101.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


64. Mathew R, Morgan MB: Dermal atypical lipomatous tumor/well-differentiated liposarcoma obfuscated by epidermal inclusion cyst: a wolf in sheep's clothing? Am J Dermatopathol; 2006 Aug;28(4):338-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal atypical lipomatous tumor/well-differentiated liposarcoma obfuscated by epidermal inclusion cyst: a wolf in sheep's clothing?
  • Epidermal inclusion cysts are an exceedingly common entity seldom seen in association with a malignant tumor.
  • Herein, we report a unique case of an epithelial inclusion cyst seen in association with an atypical lipomatous tumor/well-differentiated liposarcoma.
  • The epidermal inclusion cyst was delimited to the dermis and circumferentially enveloped by an atypical adipocyte tumor containing myxoid foci and comprised of lipoblasts.
  • This case underscores the importance of scrutinizing the entirety of cysts and other ostensibly trivial dermal entities to avoid the pitfall of misdiagnosing a potentially serious tumor.
  • [MeSH-major] Cell Differentiation. Epidermal Cyst / pathology. Liposarcoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871039.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Hatlová J, Ryska A: [What is your diagnosis? Answer: atypical lipomatous tumor with unusual hibernomatoid differentiation]. Cesk Patol; 2007 Oct;43(4):141, 159-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What is your diagnosis? Answer: atypical lipomatous tumor with unusual hibernomatoid differentiation].
  • [Transliterated title] Jaká je vase diagnóza? Odpoved': atypický lipomatózní tumor s neobvyklou hibernomatoidní diferenciací.
  • [MeSH-major] Lipoma / pathology
  • [MeSH-minor] Adipose Tissue / pathology. Female. Humans. Middle Aged. Shoulder. Subcutaneous Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188920.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


66. Fernandez-Flores A, Juanes F: Value of cytological imprints in the diagnosis of atypical lipomatous tumor. Diagn Cytopathol; 2005 Jan;32(1):51-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of cytological imprints in the diagnosis of atypical lipomatous tumor.
  • The diagnosis of atypical lipomatous tumor by biopsy, requires careful examination of several slides, in order to look for atypical cells.
  • We suggest that imprints of lipomatous tumors may play a complementary role in such a search, and report a case of a 74-yr-old woman with an atypical lipomatous tumor of the left thigh, in which imprints helped to make the diagnosis..
  • [MeSH-major] Cytodiagnosis / methods. Lipoma / pathology. Liposarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15584038.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Evans HL: Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol; 2007 Jan;31(1):1-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years.
  • Sixty-one cases of neoplasms composed wholly or in part of atypical lipomatous tumor were reviewed.
  • The cases were divided into 4 groups based on the findings in the initial excision specimen: conventional atypical lipomatous tumor (n=15), cellular atypical lipomatous tumor (n=21), dedifferentiated liposarcoma (n=24), and atypical lipomatous tumor with a pleomorphic liposarcoma-like component (n=1).
  • The term "cellular atypical lipomatous tumor" was applied to atypical lipomatous tumors having areas of increased cellularity that when non-lipogenic lacked the 5 mitotic figures per 10 high-power fields (maximal rate) required for a dedifferentiated component and when lipogenic fell short of being truly pleomorphic liposarcoma-like.
  • Myxoid regions within this spectrum sometimes had prominent or even plexiform vascularity, creating a resemblance to myxoid liposarcoma especially when interspersed small fat cells were present.
  • The most important prognostic factor was tumor location, as none of the 12 patients with a subcutaneous or intramuscular neoplasm died of tumor.
  • Among the 49 patients with neoplasms of central body sites (mostly retroperitoneum), those with dedifferentiated liposarcoma had significantly shorter survival (median 77 mo) than those with cellular (median 142 mo) or conventional (median 209 mo) atypical lipomatous tumor, whereas there was no statistically significant difference between the latter 2 categories.
  • Patients with atypical lipomatous tumor (either cellular or conventional) in central body sites had significantly shorter survival if the tumor transformed into dedifferentiated liposarcoma in recurrence, and, conversely, those with central body site dedifferentiated liposarcoma had significantly longer survival if it recurred as atypical lipomatous tumor.
  • Metastasis (7 cases) occurred only when the initial specimen or a recurrence demonstrated dedifferentiated liposarcoma.
  • [MeSH-major] Liposarcoma / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197914.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sawyer MB, Damaraju S, Pituskin E, Damaraju V, Scarfe AG, Bies RB, Hanson J, Clemons M, Kuzma M, Mackey JR: Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression. J Clin Oncol; 2009 May 20;27(15_suppl):2504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression.
  • : 2504 Background: Epirubicin (EPI) is widely used to treat breast cancer.
  • EPI is predominantly metabolized by uridine glucuronosyltransferase (UGT) 2B7 to inactive glucuronides.
  • We previously showed that a UGT enhancer single nucleotide polymorphism (SNP) at position -161 T to C correlated with rates of morphine glucuronidation.
  • METHODS: We performed a prospective pharmacogenetic study of effects of this SNP on EPI metabolism in M0 breast cancer patients (PTS) receiving adjuvant or neoadjuvant FEC100 (5-fluorouracil 500 mg/m<sup>2</sup>, EPI 100 mg/m<sup>2</sup> and cyclophosphamide 500 mg/m<sup>2</sup>) given every 3 wks.
  • PTS with ALT and AST ≤ upper limit of normal (ULN), a total bilirubin ≤ ULN, and normal renal and cardiac function were eligible.
  • EPI levels were drawn at approximately 1 and 24 hrs.
  • Cycle 1 toxicities were assessed using NCIC CTG toxicity criteria.
  • RESULTS: 123 PTS entered this study, mean (range): age 51 (28 - 74), sex 122 F/ 1 M, baseline AST 24 U/L (13-66), ALT 22 U/L (5-90), bilirubin 8 μmol/L (2-26), creatinine 74 μmol/L (50 - 126).
  • PTS were genotyped using Pyrosequencing; 26 PTS were TT homozygotes, 59 were CT heterozygotes, and 33 were CC homozygotes.
  • 5 PTS could not be genotyped.
  • A three compartment population pharmacokinetic model in NONMEM V 1.1 for EPI was used incorporating all PTS.
  • The baseline objective function was 1817, and inclusion of genotype significantly improved the objective function to 1764; CC genotype PTS had decreased EPI clearance 88.9 L/hr compared to CT/TT genotype PTS 129 L/hr, p<0.001.
  • Rates of first cycle grade 3/4 leucopenia were 78% in CC PTS and 48% in CT/TT PTS; consistent with the pharmacokinetic analysis.
  • CONCLUSIONS: A SNP in UGT 2B7 is common and appears to predicts EPI clearance and myelosuppresion in non-metastatic breast cancer PTS and may form the basis for a method to individualize EPI treatment.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a phase I study of 2 weeks of oral administration, clinical antitumor activity was observed in patients with treatment-naive nasopharyngeal carcinoma (NPC) and biological effects consistent with CDK inhibition were detected in tumor biopsy samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N: A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol; 2009 May 20;27(15_suppl):1133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Pazopanib is well tolerated and demonstrates activity in pretreated breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962243.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Phase 2 Consortium: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  • : 3521 Background: Systemic therapies have had little impact on the outcomes of patients with advanced differentiated thyroid cancers.
  • METHODS: A three-outcome one-stage Phase II trial was conducted to assess the anti-tumor activity and toxicities of the orally bioavailable VEGF/tyrosine kinase inhibitor pazopanib (800 mg daily) in patients with advanced and progressive radioiodine-insensitive differentiated thyroid cancers.
  • Overall, therapy has been well tolerated.
  • CONCLUSIONS: Pazopanib appears to have both a favorable toxicity profile and promising clinical activity in patients with advanced and progressive differentiated thyroid cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, Novotny W, Durbin B, Weston J, Hurwitz H: Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4129 Background: Preclinical data suggest that recombinant human Apo2 ligand/TNF-related apoptosis-inducing ligand (rhApo2L/TRAIL) induces tumor cell death through pro-apoptotic receptors DR4 and DR5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Mentzel T, Palmedo G, Hantschke M, Woziwodzki J, Beck C: Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity. Virchows Arch; 2008 Aug;453(2):197-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity.
  • A rare case of mixed-type liposarcoma arising in deep soft tissue of the right thigh of a 45-year-old female patient is reported.
  • The neoplasm was completely excised and was composed of an irregular admixture of areas of atypical lipomatous tumor/well-differentiated liposarcoma of the lipoma-like subtype with areas of myxoid/round cell liposarcoma.
  • An amplification of the MDM2 and CDK4 genes respectively in the atypical lipomatous tumor/well-differentiated liposarcoma areas was detected by fluorescence in situ hybridization (FISH) analysis, and translocations of the CHOP and FUS genes were detected by FISH analysis in the myxoid/round cell liposarcoma areas.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma, Myxoid / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551309.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DDIT3 protein, human; 0 / RNA-Binding Protein FUS; 147336-12-7 / Transcription Factor CHOP; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


74. Zhou WX, Liu TH: [Progress of molecular genetics and clinical application in atypical lipomatous tumor/well differentiated liposarcoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Mar;34(3):179-81
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress of molecular genetics and clinical application in atypical lipomatous tumor/well differentiated liposarcoma].
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 13. Genetic Therapy. Liposarcoma. Proto-Oncogene Proteins c-mdm2 / metabolism
  • [MeSH-minor] Animals. Humans. Retinoblastoma Protein / metabolism. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938833.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 24
  •  go-up   go-down


75. Oplatek A, Liu J, Agrawal A: Pathology quiz case 2. Atypical lipomatous tumor (ALT) of the retropharyngealspace. Arch Otolaryngol Head Neck Surg; 2008 Sep;134(9):1013, 1014-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology quiz case 2. Atypical lipomatous tumor (ALT) of the retropharyngealspace.
  • [MeSH-major] Liposarcoma / diagnosis. Mediastinal Neoplasms / diagnosis. Pharyngeal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794452.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Coindre JM, Pédeutour F, Aurias A: Well-differentiated and dedifferentiated liposarcomas. Virchows Arch; 2010 Feb;456(2):167-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated and dedifferentiated liposarcomas.
  • Atypical lipomatous tumor or well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) share the same basic genetic abnormality characterized by a simple genomic profile with a 12q14-15 amplification involving MDM2 gene.
  • This paper reviews the molecular pathology, general clinical and imaging features, histopathology, new diagnostic tools, and prognosis of ALT-WDLPS and DDLPS.
  • [MeSH-major] Liposarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688222.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 46
  •  go-up   go-down


77. Szuhai K, Ijszenga M, Knijnenburg J, Dijkstra S, de Schepper A, Tanke HJ, Hogendoorn PC: Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization. Cancer Genet Cytogenet; 2007 Jul 15;176(2):115-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization.
  • In the literature there is debate as to whether these lesions should be classified according to the criteria used in soft-tissue tumor pathology, or if they should be considered a separate bone tumor entity.
  • Here we present a 68-year-old male patient with a tumor in his right upper leg diagnosed as parosteal atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLS) on the basis of clinico-radiologic and pathologic findings.
  • Molecular cytogenetic investigations using combined binary ratio labeling fluorescence in situ hybridization and array comparative genomic hybridization showed abnormalities, which are in accordance with the histologic appearance of an atypical lipomatous tumor/well-differentiated liposarcoma.
  • Therefore, on the basis of these molecular cytogenetic investigations, we conclude that parosteal liposarcoma is not a separate entity but should be categorized within the spectrum of soft-tissue ALT/WDLS.
  • [MeSH-major] Bone Neoplasms / diagnosis. In Situ Hybridization, Fluorescence. Lipoma / diagnosis. Liposarcoma / diagnosis. Nucleic Acid Hybridization. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656253.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, Ranchere-Vince D, Terrier P, Pedeutour F: Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol; 2007 Oct;31(10):1476-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
  • Atypical lipomatous tumor/well-differentiated liposarcomas and dedifferentiated liposarcomas are characterized by the amplification of MDM2 and CDK4 genes.
  • To evaluate the accuracy of fluorescence in situ hybridization (FISH) analysis in the differential diagnosis of adipose tissue tumors, we investigated MDM2-CDK4 status by FISH, real-time polymerase chain reaction (PCR) [quantitative PCR (Q-PCR)] and immunohistochemistry (IHC) in a series of 200 adipose tumors.
  • First, we evaluated MDM2-CDK4 amplification and expression in a series of 94 well-defined adipose tissue tumors.
  • We then used the same techniques as complementary diagnostic tools in a series of 106 adipose and soft tissue tumors of unclear diagnosis to distinguish between (i) lipomas and atypical lipomatous tumor/well-differentiated liposarcomas, (ii) malignant undifferentiated tumors and dedifferentiated liposarcomas, and (iii) a variety of benign tumors and liposarcomas.
  • When tumor cells represented a minor component of the tumor tissue, such as with inflammatory tumors, FISH was more powerful than Q-PCR by allowing visualization of individual cells.
  • In conclusion, we recommend that the evaluation of MDM2-CDK4 amplification using FISH or Q-PCR be used to supplement IHC analysis when diagnosis of adipose tissue tumors is not possible based on clinical and histologic information alone.
  • [MeSH-major] Cyclin-Dependent Kinase 4 / genetics. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Lipoma / genetics. Liposarcoma / diagnosis. Nucleic Acid Amplification Techniques. Proto-Oncogene Proteins c-mdm2 / genetics. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adipocytes / metabolism. Adipocytes / pathology. Adipose Tissue / metabolism. Adipose Tissue / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Paraffin Embedding. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895748.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


79. Chen E, Fletcher CD: Cellular angiofibroma with atypia or sarcomatous transformation: clinicopathologic analysis of 13 cases. Am J Surg Pathol; 2010 May;34(5):707-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular angiofibroma is a mesenchymal neoplasm that is characterized by a bland spindle cell component, morphologically reminiscent of spindle cell lipoma, and thick-walled vessels.
  • The tumor occurs equally in men and women and usually arises in the inguino-scrotal or vulvovaginal regions.
  • An earlier study of 51 cases from our group showed that the tumor follows a benign course without any tendency for recurrence.
  • In 1 case, an intralesional microscopic nodule of pleomorphic liposarcoma was observed.
  • In this study, we characterized clinicopathologic features in 13 cases of cellular angiofibroma with morphologic atypia or sarcomatous transformation.
  • Tumor size ranged from 1.2 to 7.5 cm.
  • Most tumors were located in subcutaneous tissue.
  • Three showed severely atypical cells as scattered foci within the cellular angiofibroma.
  • One case showed a discrete nodule of atypical cells.
  • There were 9 cases of cellular angiofibroma with morphologic features of sarcomatous transformation.
  • Of these 9 cases, the sarcomatous component in 2 cases showed features of pleomorphic liposarcoma with multivacuolated lipoblasts readily identified.
  • Three of these 9 cases showed discrete nodule(s) closely resembling atypical lipomatous tumor within usual cellular angiofibroma.
  • By immunohistochemistry, atypical cells and sarcomatous areas showed either multifocal or more diffuse p16 expression compared with either scattered or negative expression in the conventional cellular angiofibroma.
  • The 3 cases with atypical lipomatous tumor-like areas were negative for MDM-2 and CDK4.
  • Cellular angiofibroma with atypia or morphologic sarcomatous transformation occurs predominantly in the subcutaneous tissue of the vulva and, as yet, shows no evident tendency to recur based on limited clinical follow-up available for 7 cases.
  • The sarcomatous component can show variable features including atypical lipomatous tumor, pleomorphic liposarcoma, and pleomorphic sarcoma NOS.
  • Overexpression of p16 in the atypical cells and sarcomatous component suggests a possible underlying molecular mechanism.
  • [MeSH-major] Angiofibroma / pathology. Cell Transformation, Neoplastic. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Vulva / pathology. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305534.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Song JS, Gardner JM, Tarrant WP, Shen S, Ayala AG, Yu E, Ro JY: Dedifferentiated liposarcoma with peculiar meningothelial-like whorling and metaplastic bone formation. Ann Diagn Pathol; 2009 Aug;13(4):278-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma with peculiar meningothelial-like whorling and metaplastic bone formation.
  • Dedifferentiated liposarcoma with peculiar meningothelial-like whorling pattern and metaplastic bone formation (DDLMB) is an unusual morphologic entity that is characterized by an atypical lipomatous tumor/well-differentiated liposarcoma with epithelioid or spindle cells concentrically arranged into meningothelial-like "whorls," and mature bone trabeculae rimmed by reactive osteoblasts.
  • Under the initial clinical diagnosis of cord lipoma in case 1 and high-grade sarcoma in case 2, the masses were removed.
  • The cut surfaces of the masses were well circumscribed with encapsulation, red-tan, firm, and multinodular.
  • Microscopically, the tumors consisted of atypical lipomatous tumor/well-differentiated liposarcoma with meningothelial-like whorls and metaplastic bone formation in both cases.
  • In addition, the first case showed focal areas of paraganglioma-like pattern; and the second case showed pleomorphic high-grade sarcoma with low-grade myxofibrosarcoma-like areas.
  • Immunohistochemically, the tumor components with meningothelial-like pattern and paraganglioma-like pattern in DDLMB were positive for vimentin and CD56 and negative for pancytokeratin, epithelial membrane antigen (EMA), desmin, and smooth muscle actin.
  • Characteristically, the paraganglioma-like area was immunoreactive for S-100 protein, with a "dot-like" staining pattern.
  • One case of dedifferentiated liposarcoma with a predominant paraganglioma-like pattern has also been reported in the literature.
  • To our knowledge, case 1 represents the first report of DDLMB with paraganglioma-like pattern.
  • A brief literature review was made with focus on the morphologic variations of DDLMB.
  • [MeSH-major] Bone and Bones / pathology. Liposarcoma / diagnosis. Liposarcoma / pathology. Osteogenesis / physiology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608088.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / S100 Proteins; 0 / Vimentin
  • [Number-of-references] 14
  •  go-up   go-down


81. Kuhnen C, Mentzel T, Sciot R, Lehnhardt M, Homann HH, Debiec-Rychter M: Dedifferentiated liposarcoma with extensive lymphoid component. Pathol Res Pract; 2005;201(4):347-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma with extensive lymphoid component.
  • An unusual variant of dedifferentiated liposarcoma with extensive lymphocytic component is described.
  • A 71-year-old patient suffered from a relapse of an atypical lipomatous tumor/well-differentiated liposarcoma with early micronodular (low-grade) dedifferentiation, which had been resected 4 years before.
  • The relapse revealed features of a dedifferentiated liposarcoma with spindle-cell, partly pleomorphic dedifferentiation and osseous metaplasia.
  • Clearly separated from the spindle-cell areas, an extensive homogeneously dense lymphoid (lymphocytic) tumor-component was evident, with relative abrupt transition to the well-differentiated liposarcoma component.
  • Using immunohistochemistry and PCR, the lymphoid ("lymphoma-like") infiltrate proved to be a polyclonal lymphocytic proliferation.
  • Fluorescence in situ hybridization (FISII) analysis revealed no signs of MDM2- and CDK4-gene amplification in the lymphoid areas, although within this mononuclear lymphoid population, large polymorphic nuclei displayed an amplified number of MDM2/CDK4 gene copies, indicating the presence of truly dedifferentiated tumor cells within the lymphoid component.
  • An extensive lymphoid "overgrowth" must be considered within the spectrum of unusual variants and in the differential diagnosis of dedifferentiated liposarcoma.
  • [MeSH-major] Liposarcoma / pathology. Lymphocytes / pathology. Lymphoid Tissue / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991843.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


82. Khan N, Afroz N, Fatima U, Raza MH, Rab AZ: Giant primary mesenteric liposarcoma: a rare case report. Indian J Pathol Microbiol; 2007 Oct;50(4):787-9
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant primary mesenteric liposarcoma: a rare case report.
  • Primary mesenteric liposarcoma is a rare malignant tumor of mesenchymal origin.
  • We report a case of primary mesenteric liposarcoma in a 55 year old man who underwent laparotomy for the clinical/radiological impression of a mesenteric cyst.
  • Histopathology showed features of atypical lipomatous tumor / well differentiated liposarcoma (ALT/WDLS) with mixed histological pattern (e.g. lipoma like, sclerosing and myxoid areas) varying from area to area.
  • Prognosis of ALT/WD liposarcoma depends upon its anatomic location and most aggressive histological subtype.
  • [MeSH-major] Liposarcoma / diagnosis. Liposarcoma / pathology. Mesentery / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306555.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


83. Panzarella MJ, Naqvi AH, Cohen HE, Damron TA: Predictive value of gadolinium enhancement in differentiating ALT/WD liposarcomas from benign fatty tumors. Skeletal Radiol; 2005 May;34(5):272-8
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of gadolinium enhancement in differentiating ALT/WD liposarcomas from benign fatty tumors.
  • OBJECTIVE: To determine the predictive value of gadolinium enhancement on MRI in differentiating atypical lipomatous tumor (ALT)/well-differentiated (WD) liposarcoma from benign fatty tumors.
  • Sensitivity, specificity, and positive and negative predictive values for both gadolinium enhancement and biopsy as predictors for the final diagnosis of ALT/WD liposarcoma were calculated.
  • RESULTS: As a predictor of ALT/WD liposarcoma, the presence of gadolinium enhancement showed 100% sensitivity, 71% specificity, 53% positive predictive value and 100% negative predictive value.
  • Needle or incisional biopsy yielded 57% sensitivity, 100% specificity, 100% positive predictive value and 63% negative predictive value for a diagnosis of ALT/WD liposarcoma.
  • CONCLUSIONS: Gadolinium enhancement of a homogeneous fatty soft tissue tumor is a sensitive screening tool to determine possible diagnosis of ALT/WD liposarcoma.
  • [MeSH-major] Contrast Media. Gadolinium. Lipoma / diagnosis. Liposarcoma / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742204.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


84. Chen X, Yu K, Tong GX, Hood M, Storper I, Hamele-Bena D: Fine needle aspiration of pleomorphic lipoma of the neck: report of two cases. Diagn Cytopathol; 2010 Mar;38(3):184-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of pleomorphic lipoma of the neck: report of two cases.
  • Pleomorphic lipoma is a rare lipocytic neoplasm that most commonly occurs in the head and neck region in middle-aged to elderly men.
  • Clinically, it presents as a slow-growing, well-circumscribed subcutaneous mass.
  • Histopathologically and cytogenetically, it has some features overlapping with other benign and malignant tumors, such as benign spindle cell lipoma, atypical lipomatous tumor, liposarcoma, and malignant fibrous histiocytoma.
  • However, cure rates are high when pleomorphic lipoma is treated with complete surgical excision with clear margins.
  • Due to the rarity of this tumor, few cases diagnosed by cytology have been reported in the English literature.
  • Here, we report two cases of pleomorphic lipoma, the diagnoses of which were suggested on fine needle aspiration biopsies and subsequently confirmed by surgical excisions.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lipoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Chromosome Aberrations. Chromosomes, Human, 16-18. Chromosomes, Human, Pair 13. Diagnosis, Differential. Fat Necrosis / diagnosis. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Middle Aged. Spinal Neoplasms / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19774616.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Laco J, Mentzel T, Hornychova H, Kohout A, Jirousek Z, Ryska A: Atypical lipomatous tumors of the tongue: report of six cases. Virchows Arch; 2009 Oct;455(4):383-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumors of the tongue: report of six cases.
  • The occurrence of liposarcoma in the tongue is rare with only 34 cases published so far.
  • We report six new cases of atypical lipomatous tumor (ALT) of the tongue, and detection of mdm-2 and CDK4 expression by immunohistochemistry and fluorescence in situ hybridization (FISH), respectively, was performed.
  • The tumors arose at the lateral side of the tongue, and in one case, multiple tumor nodules were noted.
  • Microscopically, four cases had features of lipoma-like ALT, whereas two cases displayed patterns of sclerosing ALT.
  • Immunohistochemically, tumor cells revealed expression of vimentin (five of five), S100 (five of five), mdm-2 (three of five), and CDK4 (four of five).
  • Both these markers may be of help in the differential diagnosis of ALT versus lipoma.
  • [MeSH-major] Lipoma / pathology. Liposarcoma / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816710.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Vimentin; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


86. Mentzel T, Palmedo G, Kuhnen C: Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. Mod Pathol; 2010 May;23(5):729-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases.
  • Well-differentiated spindle cell liposarcoma represents a rare atypical/low-grade malignant lipogenic neoplasm that has been regarded as a variant of atypical lipomatous tumor.
  • However, well-differentiated spindle cell liposarcoma tends to occur in subcutaneous tissue of the extremities, the trunk, and the head and neck region, contains slightly atypical spindled tumor cells often staining positively for CD34, and lacks an amplification of MDM2 and/or CDK4 in most of the cases analyzed.
  • We studied a series of well-differentiated spindle cell liposarcomas arising in two female and four male patients (age of the patients ranged from 59 to 85 years).
  • Histologically, the variably cellular neoplasms were composed of atypical lipogenic cells showing variations in size and shape, and spindled tumor cells with slightly enlarged, often hyperchromatic nuclei.
  • Immunohistochemically, CD34 was at least focally positive in all cases, whereas scattered tumor cells only showed a nuclear expression of MDM2 in two neoplasms.
  • Although well-differentiated spindle cell liposarcoma and atypical lipomatous tumor behave clinically similar, it can be speculated on the basis of clinicopathologic and molecular findings that well-differentiated spindle cell liposarcoma may constitute an independent entity rather than a morphologic variant of atypical lipomatous tumor, and may represent the atypical/low-grade counterpart of spindle cell lipoma.
  • [MeSH-major] Hand / pathology. Leg / pathology. Liposarcoma / pathology. Soft Tissue Neoplasms / pathology. Thigh / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228779.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Weaver J, Rao P, Goldblum JR, Joyce MJ, Turner SL, Lazar AJ, López-Terada D, Tubbs RR, Rubin BP: Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma? Mod Pathol; 2010 Oct;23(10):1301-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?
  • Well-differentiated liposarcoma/atypical lipomatous tumor can be difficult to differentiate from benign lipomatous tumors, especially on limited biopsy material.
  • Adjunctive tests for MDM2 (murine double minute 2) have proven useful in whole-tissue sections; however, their utility has not been determined within the increasingly popular core needle biopsy.
  • Herein, we compare the ability of MDM2 immunohistochemistry and MDM2 fluorescence in situ hybridization (FISH) to discriminate benign lipomatous tumors from well-differentiated liposarcoma on core needle biopsies.
  • Well-differentiated liposarcoma (n=17) and an assortment of benign lipomatous tumors (n=37), which had concurrent or previous core needle biopsies, and resection specimens were subjected to both MDM2 immunohistochemistry and MDM2 FISH on both whole-tissue sections and corresponding core needle biopsy sections.
  • Percentage tumor cells positive for MDM2 by immunohistochemistry and an MDM2:CEP12 FISH ratio was calculated in each biopsy and resection specimen pair and the results were compared.
  • The average MDM2:CEP12 ratio was similar in the biopsy material compared with the whole-tissue sections in both well-differentiated liposarcoma and the benign lipomatous tumor group of neoplasms.
  • Detection of MDM2 amplification by FISH is a more sensitive and specific adjunctive test than MDM2 immunohistochemistry to differentiate well-differentiated liposarcoma from various benign lipomatous tumors, especially on limited tissue samples.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Needle. Liposarcoma / diagnosis. Proto-Oncogene Proteins c-mdm2 / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lipoma / diagnosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495536.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


88. Shimada S, Ishizawa T, Ishizawa K, Matsumura T, Hasegawa T, Hirose T: The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol; 2006 Sep;37(9):1123-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
  • Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) and dedifferentiated liposarcoma (DDL) are reported to have murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) amplification as a characteristic genetic alteration.
  • To evaluate the diagnostic utility of this gene abnormality, we analyzed 19 liposarcomas, 21 malignant fibrous histiocytomas, 3 leiomyosarcomas, 5 malignant peripheral nerve sheath tumors, 23 lipomas, and 28 nonneoplastic fat tissues using real-time polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH).
  • In real-time PCR, all ALT/WDLs and DDLs had both MDM2 and CDK4 amplifications.
  • The amplification levels in ALT/WDLs and DDLs were significantly higher than those in the other sarcomas, lipomas, and nonneoplastic fat tissues (P < .05); however, those in the other sarcomas and lipomas were not significantly higher than those in nonneoplastic tissues.
  • In FISH, all ALT/WDLs and DDLs had both MDM2 and CDK4 amplifications, and all of the myxoid/round cell liposarcomas, leiomyosarcomas, malignant peripheral nerve sheath tumors, and all but one of the malignant fibrous histiocytomas did not have the amplifications.
  • In this study, MDM2 and CDK4 amplifications were confirmed in ALT/WDLs and DDLs, and the amplification levels were significantly higher than those in the other tumors.
  • An analysis of MDM2 and CDK4 amplification using real-time PCR, as well as FISH, is useful for the differential diagnosis of liposarcomas and their histologic mimickers.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase 4 / genetics. Liposarcoma / diagnosis. Liposarcoma / genetics. Proto-Oncogene Proteins c-mdm2 / genetics
  • [MeSH-minor] Adipose Tissue / pathology. Adipose Tissue / physiology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Amplification. Histiocytoma, Malignant Fibrous / diagnosis. Histiocytoma, Malignant Fibrous / genetics. Humans. In Situ Hybridization, Fluorescence. Infant. Leiomyosarcoma / diagnosis. Leiomyosarcoma / genetics. Lipoma / diagnosis. Lipoma / genetics. Male. Middle Aged. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938516.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


89. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM: MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol; 2005 Oct;29(10):1340-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
  • Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) may be difficult to distinguish from benign adipose tumors and from poorly differentiated sarcomas, respectively.
  • We examined a series of 559 soft tissue tumors (44 ALT-WDLPS, 61 DDLPS, 49 benign adipose tumors, and 405 non-ALT-WDLPS/DDLPS sarcomas) for MDM2 and CDK4 expression using immunohistochemistry.
  • Most ALT-WDLPS/DDLPS expressed MDM2 (97%) and CDK4 (92%) as opposed to few benign adipose tumors (MDM2, 5%; CDK4, 2%) and a limited number of non-ALT-WDLSP/DDLPS sarcomas (MDM2, 19%; CDK4, 6%).
  • The sensitivity and specificity of MDM2 and CDK4 immunostainings in identifying ALT-WDLPS/DDLPS among other soft tissue tumors were 97% and 92%, and 83% and 95%, respectively.
  • MDM2 and CDK4 immunostainings were particularly useful to separate ALT-WDLPS from the large group of differentiated adipose tumors, and to distinguish DDLPS from poorly differentiated sarcomas.
  • In conclusion, MDM2 and CDK4 immunostainings, which correlate with gene amplification, are helpful adjuncts to differentiate ALT-WDLPS from benign adipose tumors and to separate DDLPS from poorly differentiated sarcomas.
  • [MeSH-major] Cyclin-Dependent Kinase 4 / metabolism. Liposarcoma / diagnosis. Proto-Oncogene Proteins c-mdm2 / metabolism. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160477.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


90. He M, Aisner S, Benevenia J, Patterson F, Harrison LE, Hameed M: Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. Pathol Res Pract; 2009;205(6):386-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
  • The atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDLPS) is a locally aggressive subtype of liposarcoma unless dedifferentiation occurs.
  • Loss of p16 is believed to be an early and critical event in tumor progression.
  • Gene silencing by methylation of p16INK4a gene promoter has been reported in several soft tissue sarcomas.
  • The aim of this study is to study the role of p16INK4a gene promoter methylation and p16 expression in tumor progression (dedifferentiation) and recurrence of ALT/WDLPS.
  • Four cases of dedifferentiated liposarcomas (DDLPS) and three cases of recurrent well-differentiated liposarcomas (WDLPS) were collected, and methylation status of p16INK4a gene promoter was analyzed using methylation-specific PCR (MSP) on DNA extracted from paraffin blocks. p16 expression was examined by immunohistochemistry on the same blocks.
  • The other two DDLPS and three recurrent WDLPS were not methylated.
  • All three recurrent WDLPS showed positive p16 expression with similar intensity between primary and recurrent tumors.
  • Even though linear correlation between p16 promoter hypermethylation and p16 protein expression was not present, there appears to be a role for p16INK4a gene promoter hypermethylation in DDLPS and not in recurrent WDLPS.
  • [MeSH-major] Cell Dedifferentiation / genetics. Epigenesis, Genetic. Genes, p16. Liposarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Retinoblastoma Protein / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186005.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


91. Allon I, Vered M, Dayan D: Liposarcoma of the tongue: clinico-pathologic correlations of a possible underdiagnosed entity. Oral Oncol; 2005 Aug;41(7):657-65
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the tongue: clinico-pathologic correlations of a possible underdiagnosed entity.
  • Liposarcoma (LS), one of the most common malignant tumors, is considered as a rarity in the oral cavity, the tongue being the most frequent site for its occurrence.
  • LS of the tongue is a tumor of adult and old age, with a mean age of approximately 62 years and a peak incidence in the seventh and eighth decades.
  • Clinically, it is a long-standing tumor that commonly presents as a solitary nodular mass, but can also present as a multi-nodular lesion.
  • The most common histopathologic type is that of atypical lipomatous tumor (ALT)/well-differentiated LS (75%).
  • LS can be easily misdiagnosed with both benign and malignant lipomatous and non-lipomatous tumors.
  • When a lipomatous lesion is encountered in the oral cavity, and especially in the tongue, LS should certainly be among the lesions that top the list of differential diagnosis.
  • The follow-up must be on a long-term basis since this tumor can recur years after initial surgical treatment and can also undergo dedifferentiation.
  • [MeSH-major] Liposarcoma / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023982.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


92. Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X, Asmann YW, Lloyd RV, Jacob EK, Oliveira AM: Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol; 2009 Dec;22(12):1541-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
  • The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level.
  • However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor.
  • MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas.
  • As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors.
  • To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples.
  • All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually >20 copies per cell.
  • These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cell Differentiation. Gene Amplification. Lipoma / diagnosis. Liposarcoma / diagnosis. Metalloendopeptidases / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820690.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; EC 3.4.17.12 / carboxypeptidase M; EC 3.4.24.- / Metalloendopeptidases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


93. Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, Rubin BP, Skacel M: Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol; 2008 Aug;21(8):943-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms.
  • Well-differentiated liposarcoma/atypical lipomatous tumor and dedifferentiated liposarcoma can be difficult to distinguish from benign lipomatous neoplasms and other high-grade sarcomas, respectively.
  • Identifying MDM2 amplification by fluorescence in situ hybridization may prove an adjunctive tool in the diagnosis of lipomatous neoplasms.
  • Dual color fluorescence in situ hybridization employing a laboratory-developed BAC label probe cocktail specific for MDM2 (12q15) and a probe for the centromeric region of chromosome 12 (Abbott Molecular, DesPlaines, IL) was performed on formalin-fixed and paraffin-embedded tissue including whole sections from atypical lipomatous tumors (n=13), dedifferentiated liposarcomas (n=14), benign lipomatous tumors (n=30), and pleomorphic sarcoma, not otherwise specified (n=10), and a tissue microarray containing a variety of high-grade sarcomas (n=63).
  • Of the well-differentiated and dedifferentiated liposarcomas, 100% showed amplification of MDM2.
  • MDM2/chromosome 12 fluorescence in situ hybridization is a sensitive and specific tool (both 100%) in evaluating low-grade lipomatous neoplasms.
  • The specificity decreases in high-grade sarcomas, as MDM2 amplification was observed in a small portion of pleomorphic sarcomas and high-grade sarcomas other than dedifferentiated liposarcomas.
  • Importantly, none of the benign lipomatous lesions were MDM2 amplified and even cells in areas of well-differentiated liposarcomas with minimal cytologic atypia were amplified, making the probe a valuable tool in the diagnosis of even limited biopsy samples of well-differentiated lipomatous neoplasms.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Lipoma / genetics. Liposarcoma / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Aneuploidy. Chromosomes, Human, Pair 12. Gene Amplification. Humans. Nucleic Acid Amplification Techniques. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500263.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


94. Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, Lev DC, Pollock RE: Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. Ann Surg Oncol; 2009 Mar;16(3):667-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histology stratified patients into three groups by prognosis (P<0.0002): atypical lipomatous tumor (ALT), non-ALT liposarcoma (LPS), and "other," an improvement compared with AJCC staging which could only identify two distinct prognostic groups.
  • Distinct risk stratification is critical for specific assessment of prognosis as well as decisions regarding individualized adjuvant therapies, hence the advantage of a three-tiered histology-based system applicable in both primary and recurrent RPS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101765.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Miyakura T, Irisawa R, Miyamoto M, Iwaya K, Yamamoto T, Tsuboi R: An atypical case of atypical lipomatous tumor. Am J Dermatopathol; 2008 Dec;30(6):590-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical case of atypical lipomatous tumor.
  • The nodule was about 11x7 cm in diameter with a well-demarcated, smooth, surface.
  • Immunohistochemically, some of the tumor cells were positive for p53 and MDM2.
  • Histologically, the atypical lipomatous tumor, lipoblastoma, spindle cell lipoma, pleomorphic liposarcoma, and hibernoma comprised the list of possible, differential diagnoses.
  • We considered our case to be a variant of atypical lipomatous tumor, although it did not correspond to any of the 4 atypical lipomatous tumor subgroups.
  • [MeSH-major] Adipocytes / pathology. Liposarcoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033936.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


96. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common laboratory abnormality was ALT elevation (53%; 10% Gr 3; 2% Gr 4).
  • CONCLUSIONS: Pazopanib monotherapy was well tolerated and demonstrated a significant improvement in PFS and RR compared to placebo.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Rougier P, Infante J, Van Laethem J, Stephenson JJ, Uronis H, Schwartzberg L, Chen L, Wu C, Smethurst D, Peeters M: A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. J Clin Oncol; 2009 May 20;27(15_suppl):4130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In part 1, pts received pmab 6 mg/kg Q2W plus AMG 655 at a starting dose of 10 mg/kg (evaluation of subsequent doses of 3 mg/kg or 1 mg/kg if needed; 6-9 pts at each dose) by sequential intravenous infusion at week 1 and Q2W thereafter until PD or intolerability.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kolevska T, Ryan CJ, Huey V, Weisberg L, Wang S, Baer D, Ghadialy A, Goldstein D, Fireman B, Fehrenbacher L: Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This regimen was well tolerated, and may be useful in patients who are not suitable candidates for docetaxel based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964449.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakayama N, Mashiko S, Yamazaki R, Kaneko N, Futagawa S, Nagaoka I: Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level. J Clin Oncol; 2009 May 20;27(15_suppl):e15110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level.
  • : e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985).
  • However, the correlation to prognosis has not been evaluated.
  • The aim of this study was to evaluate the correlation between prognosis and serum-iron level in advanced / metastatic colorectal cancer (aCRC / mCRC) patients treated by FOLFOX / FOLFIRI.
  • METHODS: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008.
  • 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis.
  • These patients were categorized into the high increase group and the low increase group using 200% increase as cut-off value and the prognosis was compared.
  • RESULTS: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001).
  • This increase was transient and returns to pre chemotherapy level by the start of next course.
  • This alteration was always observed on the chemotherapy.
  • The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004).
  • The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed.
  • CONCLUSIONS: It is suggested that serum-iron increase is a biological response not attributed to leakage from erythrocyte and hepatocyte.
  • Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Doğan R, Kara M, Yazicioğlu A, Onder S: Giant atypical lipomatous tumor of the mediastinum. Tuberk Toraks; 2008;56(1):100-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant atypical lipomatous tumor of the mediastinum.
  • Atypical lipomatous tumors, so-called well differentiated liposarcomas are the intermediate or locally aggressive form of adipocytic tumors.
  • We herein report a case with a giant atypical lipomatous tumor located at the mediastinum that was surgically excised.
  • Surgery remains as the treatment of choice for mediastinal liposarcomas.
  • [MeSH-major] Liposarcoma / surgery. Mediastinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330763.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down






Advertisement